<?xml version="1.0" encoding="UTF-8"?>
<record
    xmlns:xsi="https://www.w3.org/2001/XMLSchema-instance"
    xsi:schemaLocation="https://www.loc.gov/MARC21/slim https://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd"
    xmlns="https://www.loc.gov/MARC21/slim">

  <leader>01840nam a2200265   4500</leader>
  <controlfield tag="001">387624</controlfield>
  <datafield tag="010" ind1=" " ind2=" ">
    <subfield code="a">9789291683420</subfield>
  </datafield>
  <datafield tag="090" ind1=" " ind2=" ">
    <subfield code="a">387624</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">20090420d2008       y0pory50      ba</subfield>
  </datafield>
  <datafield tag="101" ind1=" " ind2=" ">
    <subfield code="a">eng</subfield>
  </datafield>
  <datafield tag="200" ind1=" " ind2=" ">
    <subfield code="a">National drug-related research in Europe</subfield>
    <subfield code="f">European Monitoring Centre for Drugs and Drug Addiction</subfield>
  </datafield>
  <datafield tag="210" ind1=" " ind2=" ">
    <subfield code="a">Luxembourg</subfield>
    <subfield code="c">Office for Official Publications of the European Communities</subfield>
    <subfield code="d">2008</subfield>
  </datafield>
  <datafield tag="215" ind1=" " ind2=" ">
    <subfield code="a">29 p.</subfield>
    <subfield code="d">30 cm</subfield>
  </datafield>
  <datafield tag="330" ind1=" " ind2=" ">
    <subfield code="a">Introductory note and acknowledgements. Introduction. Methodology. Previous and current EU work on drug-related research in Europe. National frameworks for drug-related research. Drug-related research in national policy. Examples of specialised drug-related research centres in Europe. A challenge to quality in research: lack of coordination. Funding arrangements. Funding rationales and priorities. Difficulties in quantifying expenditures on drug-related research. Limitations and gaps in drug-related research. A recent history of drug-related research in Europe. Research priorites in some reporting countries. Zooming in on five main studies in each country. The interface between research, policy and practice. Drug-related journals. Drug-related research dissemination. Internet and dedicated websites. Other dissemination channels. Conclusions. 12 years later, where are we now? Future developments in drug-related research. References.</subfield>
  </datafield>
  <datafield tag="606" ind1=" " ind2=" ">
    <subfield code="a">COMBATE &#xC0; DROGA</subfield>
    <subfield code="9">410441</subfield>
  </datafield>
  <datafield tag="606" ind1=" " ind2=" ">
    <subfield code="a">PREVEN&#xC7;&#xC3;O DA TOXICODEPEND&#xCA;NCIA</subfield>
    <subfield code="9">103892</subfield>
  </datafield>
  <datafield tag="606" ind1=" " ind2=" ">
    <subfield code="a">OEDT</subfield>
    <subfield code="9">321506</subfield>
  </datafield>
  <datafield tag="606" ind1=" " ind2=" ">
    <subfield code="a">RELAT&#xD3;RIO</subfield>
    <subfield code="9">410454</subfield>
  </datafield>
  <datafield tag="710" ind1=" " ind2=" ">
    <subfield code="a">EUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION</subfield>
    <subfield code="9">351987</subfield>
  </datafield>
  <datafield tag="955" ind1=" " ind2=" ">
    <subfield code="x">Oferta</subfield>
  </datafield>
  <datafield tag="995" ind1=" " ind2=" ">
    <subfield code="1">0</subfield>
    <subfield code="4">PJ_20_000000000000000_B_3</subfield>
    <subfield code="5">2022-06-06</subfield>
    <subfield code="6">PJ29921</subfield>
    <subfield code="9">418624</subfield>
    <subfield code="a">PJ</subfield>
    <subfield code="c">PJ</subfield>
    <subfield code="f">PJ129921</subfield>
    <subfield code="k">PJ20.B.3</subfield>
    <subfield code="n">2022-06-06</subfield>
    <subfield code="o">0</subfield>
    <subfield code="r">MO</subfield>
    <subfield code="x">Oferta</subfield>
  </datafield>
</record>
